$5.31
16.19% yesterday
Nasdaq, Aug 12, 10:03 pm CET
ISIN
US68062P1066
Symbol
OLMA

Olema Pharmaceuticals Inc Stock price

$5.31
+0.48 9.94% 1M
+0.37 7.49% 6M
-0.52 8.92% YTD
-6.89 56.48% 1Y
+1.25 30.79% 3Y
-13.69 72.05% 5Y
-13.69 72.05% 10Y
-13.69 72.05% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.74 16.19%
ISIN
US68062P1066
Symbol
OLMA
Industry

Key metrics

Basic
Market capitalization
$312.7m
Enterprise Value
$-80.0m
Net debt
positive
Cash
$392.7m
Shares outstanding
68.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.6
P/B
0.8
Financial Health
Equity Ratio
90.7%
Return on Equity
-31.7%
ROCE
-37.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-142.4m | $-153.8m
EBIT
$-142.8m | $-157.1m
Net Income
$-128.9m | $-118.8m
Free Cash Flow
$-124.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-30.2% | -8.4%
EBIT
-30.2% | -10.4%
Net Income
-29.7% | 8.2%
Free Cash Flow
-43.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.5
FCF per Share
$-1.8
Short interest
12.3%
Employees
85
Rev per Employee
$0.0
Show more

Is Olema Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Olema Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Olema Pharmaceuticals Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Olema Pharmaceuticals Inc forecast:

Buy
93%
Hold
7%

Financial data from Olema Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
6% 6%
-
- Research and Development Expense 125 125
34% 34%
-
-142 -142
30% 30%
-
- Depreciation and Amortization 0.43 0.43
16% 16%
-
EBIT (Operating Income) EBIT -143 -143
30% 30%
-
Net Profit -129 -129
30% 30%
-

In millions USD.

Don't miss a Thing! We will send you all news about Olema Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Olema Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
one day ago
SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the second quarter ended June 30, 2025.
Neutral
GlobeNewsWire
8 days ago
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 130,000 shares...
Neutral
GlobeNewsWire
about one month ago
SAN FRANCISCO, July 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 154,500 shares...
More Olema Pharmaceuticals Inc News

Company Profile

Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Head office United States
CEO Sean Bohen
Employees 85
Founded 2006
Website olema.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today